Cough; dyspnea; GI symptoms; malaise; SARS-CoV-2 Infection Following Vaccination; arthralgia; myalgia; fatigue; This literature-non-study case was reported in a literature article and describes the occurrence of COUGH (Cough), DYSPNOEA (dyspnea), GASTROINTESTINAL DISORDER (GI symptoms), MALAISE (malaise), COVID-19 (SARS-CoV-2 Infection Following Vaccination), ARTHRALGIA (arthralgia), MYALGIA (myalgia) and FATIGUE (fatigue) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.   LITERATURE REFERENCE: Chonchol, Lx J, Ginsberg c.. Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients. Am J Kidney Dis. 2021;78:314-317     The patient's past medical history included Kidney transplant (6 years ago). Concurrent medical conditions included Hypertension. Concomitant products included TACROLIMUS and MYCOPHENOLATE MOFETIL (MYCOPHENOLATE) for an unknown indication.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COUGH (Cough) (seriousness criterion medically significant), DYSPNOEA (dyspnea) (seriousness criterion medically significant), GASTROINTESTINAL DISORDER (GI symptoms) (seriousness criterion medically significant), MALAISE (malaise) (seriousness criterion medically significant), ARTHRALGIA (arthralgia) (seriousness criterion medically significant), MYALGIA (myalgia) (seriousness criterion medically significant) and FATIGUE (fatigue) (seriousness criterion medically significant). an unknown date, the patient experienced COVID-19 (SARS-CoV-2 Infection Following Vaccination) (seriousness criterion medically significant). At the time of the report, COUGH (Cough), DYSPNOEA (dyspnea), GASTROINTESTINAL DISORDER (GI symptoms), MALAISE (malaise), COVID-19 (SARS-CoV-2 Infection Following Vaccination), ARTHRALGIA (arthralgia), MYALGIA (myalgia) and FATIGUE (fatigue) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Blood creatinine: borderline (Borderline) 1.86mg/dL. In 2021, Body mass index: high (High) 36.4 kg/ m2. In 2021, SARS-CoV-2 test: positive (Positive) positive. Meets Centers for Disease Control and Prevention criteria for breakthrough COVID-19.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered COUGH (Cough), DYSPNOEA (dyspnea), GASTROINTESTINAL DISORDER (GI symptoms), MALAISE (malaise), COVID-19 (SARS-CoV-2 Infection Following Vaccination), ARTHRALGIA (arthralgia), MYALGIA (myalgia) and FATIGUE (fatigue) to be unlikely related.    Patient blood group is A. Patient Meets Centers for Disease Control and Prevention criteria for breakthrough COVID-19. Treatment medication not provided  Based on reporter's causality and the fact that the patient is under continuous immunosuppressive therapy following organ transplantation, the events are assessed as unlikely related to mRNA-1273. All events described here can be considered as symptoms of a Covid-19 infection which is described in this literature report as a breakthrough infection following the complete vaccination as required. The patient did not develop antibodies against the spike protein which is another indicator why the vaccination did not prevent a Covid-19 infection in this patient.; Sender's Comments: Based on reporter's causality and the fact that the patient is under continuous immunosuppressive therapy following organ transplantation, the events are assessed as unlikely related to mRNA-1273. All events described here can be considered as symptoms of a Covid-19 infection which is described in this literature report as a breakthrough infection following the complete vaccination as required. The patient did not develop antibodies against the spike protein which is another indicator why the vaccination did not prevent a Covid-19 infection in this patient.